Brian Meshkin

Brian Meshkin is an entrepreneur who founded the genetic testing companies Salugen, Inc., and Proove Biosciences.

Brian Meshkin
Nationality US
Occupation Businessman
Website https://brianmeshkin.com/

Surfbuzz.com

In November 1999, Meshkin co-founded internet incentives company Surfbuzz.com with his brother, Alex.[1] Surfbuzz folded the following year after burning through between $3 million and $4 million in seed money.[2][3][4]

Salugen, Inc.

Salugen, Inc., incorporated in April 2005,[5] sold dietary supplements and direct-to-consumer (DTC) genetic tests -- a relatively new business model that was lightly regulated at that time.[6] In June 2008, the California Department of Public Health issued cease-and-desist notices to 13 genetics companies, including Salugen, for improper marketing of DTC tests.[7][8][9] Salugen was ordered not to test Californians until it was licensed as a clinical laboratory in California, and to perform only validated tests ordered by a licensed physician.[7] On 10 September, 2008, Salugen executives other than CEO Meshkin resigned, citing the firm's inability "to raise capital, adequately perform operational activities or compensate employees and vendors" under his direction.[10] Soon afterwards Salugen was acquired by Sherbrooke Equity A.G. Despite raising further capital on the Frankfurt Stock Exchange, Salugen was wound up the following year.

Proove Biosciences

Meshkin founded Proove Biosciences in December 2009.[1] Proove Biosciences began marketing a test called the "Proove Opioid Risk test" (POR) which it claimed could predict with high accuracy which patients would become addicted to or misuse prescribed opioid pain pills. Other Proove products included Proove Pain Perception, Proove Opioid Response, and Proove Drug Metabolism.[11]

Proove Bioscience's business model involved practices that appeared to generate potential conflicts of interest. Proove Biosciences was running research programs out of hospital clinics. In fact, more than 90% of patients tested were enrolled on clinical studies administered by Proove.[11] Proove offered a payment to clinicians for each patient recruited to these studies. This arrangement could have given clinicians a financial incentive to enroll patients to research program, and thereby enrich Proove Biosciences by allowing insurance reimbursement for those patients.[12][13] Further concerns were raised when scientists and clinicians expressed reservations about the quality of the evidence supporting the POR.[11][13][14][15] Former employees said that Meshkin, who has no background in science, asserted control over the company's research program: "It was marketing. It wasn’t science."[13]

In May 2017, a whistleblower lawsuit filed against Proove Biosciences in 2015 by Bruce Gardner, a former employee, was unsealed.[16] The complaint alleges that Proove submitted false claims to Medicare in violation of the False Claims Act and federal Anti-Kickback Statute. The suit asserts that Proove billed for medically unnecessary genetic tests and engaged in a sophisticated kickback scheme with physicians.[16]

On 7 June 2017, the FBI raided the offices of Proove Biosciences in Irvine, CA, in relation to an investigation of health care fraud.[17] On 7 August, 2017, Proove Biosciences was placed into court-ordered receivership. On August 31, 2017, it was reported that Meshkin was no longer CEO at Proove Biosciences.[18]

References

  1. 1 2 "Brain Meshkin". LinkedIn. Retrieved 23 June 2018.
  2. ↑ "Wipeout! Surfbuzz Goes Under". Wired. 6 June 2000. Retrieved 23 June 2018. If ever a startup embraced the whole make-a-fast-buck, dot-com ethos, it was Surfbuzz.com, an auction site that awarded expensive prizes to its customers. The only buzzing to be heard now is from the flies swarming over the corpse of Surfbuzz, which said Tuesday that it is going out of business.
  3. ↑ Walker, Leslie (25 November 1999). "Brothers With a Selling Point". Washington Post. Retrieved 26 June 2018.
  4. ↑ Dean, Katie (26 October 1999). "Teen trades education for e-biz". Wired. Retrieved 26 June 2018.
  5. ↑ "The Story Of Salugen". Salugen. Retrieved 23 June 2018.
  6. ↑ Kaye, Jane (2008). "The Regulation of Direct-to-Consumer Genetic Tests". Hum Mol Genet. 17 (R2): R180–R183. doi:10.1093/hmg/ddn253.
  7. 1 2 "Genetic Test Cease-And-Desist Notices". California Department of Public Health. 24 June 2008. Archived from the original on 2 July 2008. Retrieved 27 June 2018.
  8. ↑ Johnson, Steve (24 June 2008). "Five California gene testing firms among 13 suspended". Mercury News. Retrieved 27 June 2018.
  9. ↑ "Big Genetics Company Conducted Needless, Inaccurate Tests, Employees Say - KQED Future of You". KQED. 1 February 2017. Retrieved 2 September 2018.
  10. ↑ "The Salugen Story Reconstructed". Tales of Two Cities. 2 September 2012. Retrieved 23 June 2018.
  11. 1 2 3 Gusovsky, Dina (2016-05-06). "A medical test that aims to wean America off painkillers". CNBC. Retrieved 26 June 2018.
  12. ↑ Daley, Beth (3 October 2015). "Genetic tests for psychiatric drugs spur hope, doubts: Business unregulated and science often thin, critics say". Boston Globe. Retrieved 24 June 2018.
  13. 1 2 3 Piller, Charles (28 Feb 2017). "It's easy money: Lab offers doctors up to $144,000 a year to push dubious genetic tests, employees say". STAT. Retrieved 24 June 2018.
  14. ↑ Piller, Charles (13 December 2016). "Called 'hogwash,' a gene test for addiction risk exploits opioid fears". STAT. Retrieved 23 June 2018.
  15. ↑ Siegel, Zachary (16 October 2016). "Can a DNA Test Really Predict Opiate Addiction?". The Daily Beast. Retrieved 26 June 2018.
  16. 1 2 "Mintz Levin Health Care Qui Tam Update - Recently Unsealed Whistleblower Cases: August 2017". JDSupra. 7 August 2017. Retrieved 15 July 2018. The relator alleges that Proove engaged in fraudulent billing practices in connection with a series of genetic tests designed to determine patients’ susceptibility to opioid addiction based on their genetic profiles... The complaint alleges that Proove’s genetic tests are unsupported by medical evidence, and the defendant billed Medicare and Medicaid for medically unnecessary tests using billing codes that were inapplicable to the genetic tests it was actually performing but which generated higher reimbursements. In addition, the complaint asserts that the defendant improperly induced physicians to sign a Professional Services Agreement to sell and administer Proove’s tests to patients in exchange for a fee from Proove and reimbursement from Medicare. The relator alleges that this complicated kickback scheme resulted in Medicare’s payment of millions of dollars for unnecessary and expensive testing.
  17. ↑ Piller, Charles (8 June 2017). "FBI raids offices of lab that pays doctors to promote genetic tests". STAT. Retrieved 23 June 2018.
  18. ↑ Piller, Charles (31 August 2017). "Proove Biosciences, which sold dubious DNA tests to predict addiction risk, sells off assets as CEO departs amid criminal probe". STAT. Retrieved 23 June 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.